Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

The purpose of this study was to analyze the postoperative pancreatic morbidity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal surface malignancies (PSM).
Two hundred and sixty five patients (87M/178F) with PSM underwent 270 consecutive procedures. The mean age was 52 years (range: 22-79 years). CRS was performed using peritonectomy procedures. HIPEC through the closed abdomen technique was conducted using cisplatin (CDDP 25 mg/m2/L of perfusate)+mitomycin C (MMC 3.3 mg/m2/L of perfusate) or CDDP (43 mg/L of perfusate)+doxorubicin (Dx 15.25 mg/L of perfusate), at 42.5 degrees C. Diagnosis and classification of postoperative pancreatic fistula (POPF) were performed according to the international study group on pancreatic fistula criteria. Serum amylase alterations were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v3.
POPF was observed in 13 (4.8%) cases. Three cases were classified as major (grade C). Two cases presented postoperative pancreatitis. G3-4 alteration of amylase was observed in 12.3% of the cases. Performing splenectomy and CDDP dosage for HIPEC >240 mg were proven to be independent risk factors for both G3-4 hyperamylasemia and POPF.
CRS+HIPEC presented an acceptable rate of pancreatic morbidity which did not contribute to the mortality related to the procedure. Most of the POPF were mild and/or easily controlled by conservative measures. Although not specific a normal amylasemia could be a useful marker of pancreatic integrity after CRS+HIPEC.
AuthorsShigeki Kusamura, Dario Baratti, Adelmo Antonucci, Rami Younan, Barbara Laterza, Grazia Daniela Oliva, Cecilia Gavazzi, Marcello Deraco
JournalAnnals of surgical oncology (Ann Surg Oncol) Vol. 14 Issue 12 Pg. 3443-52 (Dec 2007) ISSN: 1534-4681 [Electronic] United States
PMID17909918 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Mitomycin
  • Doxorubicin
  • Cisplatin
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cisplatin (administration & dosage)
  • Combined Modality Therapy
  • Doxorubicin (administration & dosage)
  • Female
  • Humans
  • Hyperamylasemia (etiology, pathology)
  • Hyperthermia, Induced
  • Infusions, Parenteral
  • Male
  • Middle Aged
  • Mitomycin (administration & dosage)
  • Morbidity
  • Neoplasm Recurrence, Local
  • Pancreatic Fistula (etiology, pathology)
  • Peritoneal Neoplasms (drug therapy, surgery)
  • Postoperative Complications (etiology, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: